;PMID: 1988174 ;source_file_1007.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..37] = [t:0..37] ;1)sentence:[e:43..197] = [t:43..197] ;2)section:[e:201..275] = [t:201..275] ;3)section:[e:279..331] = [t:279..331] ;4)sentence:[e:335..561] = [t:335..561] ;5)sentence:[e:562..803] = [t:562..803] ;6)sentence:[e:804..914] = [t:804..914] ;7)sentence:[e:915..1225] = [t:915..1225] ;8)sentence:[e:1226..1383] = [t:1226..1383] ;9)sentence:[e:1384..1704] = [t:1384..1704] ;10)sentence:[e:1705..1846] = [t:1705..1846] ;11)sentence:[e:1847..2003] = [t:1847..2003] ;12)sentence:[e:2004..2159] = [t:2004..2159] ;13)sentence:[e:2160..2350] = [t:2160..2350] ;14)sentence:[e:2351..2559] = [t:2351..2559] ;15)section:[e:2563..2607] = [t:2563..2607] ;section 0 Span:0..37 ;Carcinogenesis. 1991 Jan;12(1):133-9. (SEC (FRAG (RB:[0..14] Carcinogenesis) (IN:[14..15] .) (CD:[16..20] 1991) (CC:[21..28] Jan;12-LRB-) (CD:[28..29] 1) (-RRB-:[29..30] -RRB-) (CD:[30..34] :133) (::[34..35] -) (CD:[35..37] 9.))) ;sentence 1 Span:43..197 ;Roles of different cytochrome P450 enzymes in bioactivation of the potent ;hepatocarcinogen 3-methoxy-4-aminoazobenzene by rat and human liver ;microsomes. ;[62..85]:cyp450:"cytochrome P450 enzymes" ;[118..134]:substance:"hepatocarcinogen" ;[135..162]:substance:"3-methoxy-4-aminoazobenzene" (SENT (NP-HLN (NP (NNS:[43..48] Roles)) (PP (IN:[49..51] of) (NP (JJ:[52..61] different) (NML (NN:[62..72] cytochrome) (NN:[73..77] P450)) (NNS:[78..85] enzymes))) (PP (IN:[86..88] in) (NP (NP (NN:[89..102] bioactivation)) (PP (IN:[103..105] of) (NP (NP (DT:[106..109] the) (JJ:[110..116] potent) (NN:[118..134] hepatocarcinogen)) (NP (NN:[135..162] 3-methoxy-4-aminoazobenzene)))) (PP (IN:[163..165] by) (NP (NP (NN:[166..169] rat) (NML-1 (-NONE-:[169..169] *P*))) (CC:[170..173] and) (NP (JJ:[174..179] human) (NML-1 (NN:[180..185] liver) (NNS:[186..196] microsomes))))))) (.:[196..197] .))) ;section 2 Span:201..275 ;Yamazaki H, Degawa M, Funae Y, Imaoka S, Inui Y, Guengerich FP, Shimada T. (SEC (FRAG (NNP:[201..209] Yamazaki) (NNP:[210..211] H) (,:[211..212] ,) (NNP:[213..219] Degawa) (NNP:[220..222] M,) (NNP:[223..228] Funae) (NNP:[229..230] Y) (,:[230..231] ,) (NNP:[232..238] Imaoka) (NNP:[239..241] S,) (NNP:[242..246] Inui) (NNP:[247..248] Y) (,:[248..249] ,) (NNP:[250..260] Guengerich) (NNP:[261..263] FP) (,:[263..264] ,) (NNP:[265..272] Shimada) (NNP:[273..275] T.))) ;section 3 Span:279..331 ;Osaka Prefectural Institute of Public Health, Japan. (SEC (FRAG (NNP:[279..284] Osaka) (NNP:[285..296] Prefectural) (NNP:[297..306] Institute) (IN:[307..309] of) (NNP:[310..316] Public) (NNP:[317..323] Health) (,:[323..324] ,) (NNP:[325..330] Japan) (.:[330..331] .))) ;sentence 4 Span:335..561 ;The potent hepatocarcinogen 3-methoxy-4-aminoazobenzene (3-MeO-AAB) has been ;reported to be bioactivated to mutagenic intermediates by rat liver ;microsomal cytochrome P450 (P450) and to be a selective inducer of rat ;P450IA2. ;[346..362]:substance:"hepatocarcinogen" ;[363..390]:substance:"3-methoxy-4-aminoazobenzene" ;[392..401]:substance:"3-MeO-AAB" ;[454..467]:substance:"intermediates" ;[493..508]:cyp450:"cytochrome P450" ;[510..514]:cyp450:"P450" ;[538..545]:substance:"inducer" ;[553..560]:cyp450:"P450IA2" (SENT (S (NP-SBJ-2 (DT:[335..338] The) (JJ:[339..345] potent) (NN:[346..362] hepatocarcinogen) (NP (NP (NN:[363..390] 3-methoxy-4-aminoazobenzene)) (NP (-LRB-:[391..392] -LRB-) (NN:[392..401] 3-MeO-AAB) (-RRB-:[401..402] -RRB-)))) (VP (VBZ:[403..406] has) (VP (VBN:[407..411] been) (VP (VBN:[413..421] reported) (NP-2 (-NONE-:[421..421] *)) (S (NP-SBJ-1 (-NONE-:[421..421] *)) (VP (VP (TO:[422..424] to) (VP (VB:[425..427] be) (VP (VBN:[428..440] bioactivated) (NP-1 (-NONE-:[440..440] *)) (PP (TO:[441..443] to) (NP (JJ:[444..453] mutagenic) (NNS:[454..467] intermediates))) (PP (IN:[468..470] by) (NP-LGS (NN:[471..474] rat) (NN:[475..480] liver) (JJ:[481..491] microsomal) (NML (NML (NN:[493..503] cytochrome) (NN:[504..508] P450)) (NML (-LRB-:[509..510] -LRB-) (NN:[510..514] P450) (-RRB-:[514..515] -RRB-)))))))) (CC:[516..519] and) (VP (TO:[520..522] to) (VP (VB:[523..525] be) (NP-PRD (NP (DT:[526..527] a) (JJ:[528..537] selective) (NN:[538..545] inducer)) (PP (IN:[546..548] of) (NP (NN:[549..552] rat) (NN:[553..560] P450IA2))))))))))) (.:[560..561] .))) ;sentence 5 Span:562..803 ;In this study we have further investigated the roles of individual rat and ;human P450 enzymes in the bioactivation of this hepatocarcinogen in a ;Salmonella typhimurium TA1535/pSK1002 system where umu response is ;indicative of DNA damage. ;[644..657]:cyp450:"P450 enzymes" ;[687..703]:substance:"hepatocarcinogen" ;[791..794]:substance:"DNA" (SENT (S (PP (IN:[562..564] In) (NP (DT:[565..569] this) (NN:[571..576] study))) (NP-SBJ (PRP:[577..579] we)) (VP (VBP:[580..584] have) (ADVP (RBR:[585..592] further)) (VP (VBN:[593..605] investigated) (NP (NP (DT:[606..609] the) (NNS:[610..615] roles)) (PP (IN:[616..618] of) (NP (NP (ADJP-3 (JJ:[619..629] individual)) (NN:[630..633] rat) (NML-2 (-NONE-:[633..633] *P*))) (CC:[634..637] and) (NP (ADJP-3 (-NONE-:[637..637] *P*)) (JJ:[638..643] human) (NML-2 (NN:[644..648] P450) (NNS:[650..657] enzymes)))))) (PP (IN:[658..660] in) (NP (NP (DT:[661..664] the) (NN:[665..678] bioactivation)) (PP (IN:[679..681] of) (NP (DT:[682..686] this) (NN:[687..703] hepatocarcinogen))) (PP (IN:[704..706] in) (NP (NP (DT:[707..708] a) (NNP:[709..719] Salmonella) (NNP:[721..732] typhimurium) (NML (NN:[733..739] TA1535) (SYM:[739..740] /) (NN:[740..747] pSK1002)) (NN:[748..754] system)) (SBAR (WHADVP-1 (WRB:[755..760] where)) (S (NP-SBJ (NN:[761..764] umu) (NN:[765..773] response)) (VP (VBZ:[774..776] is) (ADJP-PRD (JJ:[777..787] indicative) (PP (IN:[788..790] of) (NP (NN:[791..794] DNA) (NN:[796..802] damage)))) (ADVP-1 (-NONE-:[802..802] *T*))))))))))) (.:[802..803] .))) ;sentence 6 Span:804..914 ;3-MeO-AAB was found to be bioactivated by liver microsomal enzymes from rats ;and humans in this assay system. ;[804..813]:substance:"3-MeO-AAB" ;[863..870]:substance:"enzymes" (SENT (S (NP-SBJ-1 (NN:[804..813] 3-MeO-AAB)) (VP (VBD:[814..817] was) (VP (VBN:[818..823] found) (S (NP-SBJ-1 (-NONE-:[823..823] *)) (VP (TO:[824..826] to) (VP (VB:[827..829] be) (VP (VBN:[830..842] bioactivated) (NP-1 (-NONE-:[842..842] *)) (PP (IN:[843..845] by) (NP-LGS (NP (NN:[846..851] liver) (JJ:[852..862] microsomal) (NNS:[863..870] enzymes)) (PP (IN:[871..875] from) (NP (NNS:[877..881] rats) (CC:[882..885] and) (NNS:[886..892] humans))))) (PP (IN:[893..895] in) (NP (DT:[896..900] this) (NN:[901..906] assay) (NN:[907..913] system))))))))) (.:[913..914] .))) ;sentence 7 Span:915..1225 ;The liver microsomal activities are increased by pretreatment of rats with ;various P450 inducers such as phenobarbital (PB), beta-naphthoflavone (BNF), ;dexamethasone (DEX), acetone, ethanol, isoniazid (INH), diphenylhydantoin ;and valproic acid, and can be inhibited considerably by SKF-525A and ;metyrapone. ;[999..1003]:cyp450:"P450" ;[1004..1012]:substance:"inducers" ;[1022..1035]:substance:"phenobarbital" ;[1037..1039]:substance:"PB" ;[1042..1061]:substance:"beta-naphthoflavone" ;[1063..1066]:substance:"BNF" ;[1069..1082]:substance:"dexamethasone" ;[1084..1087]:substance:"DEX" ;[1090..1097]:substance:"acetone" ;[1100..1107]:substance:"ethanol" ;[1109..1118]:substance:"isoniazid" ;[1120..1123]:substance:"INH" ;[1126..1143]:substance:"diphenylhydantoin" ;[1148..1161]:substance:"valproic acid" ;[1201..1209]:substance:"SKF-525A" ;[1214..1224]:substance:"metyrapone" (SENT (S (NP-SBJ-1 (DT:[915..918] The) (NN:[919..924] liver) (JJ:[925..935] microsomal) (NNS:[936..946] activities)) (VP (VP (VBP:[947..950] are) (VP (VBN:[952..961] increased) (NP-1 (-NONE-:[961..961] *)) (PP (IN:[962..964] by) (NP-LGS (NP (NN:[965..977] pretreatment)) (PP (IN:[978..980] of) (NP (NNS:[981..985] rats))) (PP (IN:[986..990] with) (NP (NP (JJ:[991..998] various) (NN:[999..1003] P450) (NNS:[1004..1012] inducers)) (PP (JJ:[1013..1017] such) (IN:[1018..1020] as) (NP (NP (NP (NN:[1022..1035] phenobarbital)) (NP (-LRB-:[1036..1037] -LRB-) (NN:[1037..1039] PB) (-RRB-:[1039..1040] -RRB-))) (,:[1040..1041] ,) (NP (NP (NN:[1042..1061] beta-naphthoflavone)) (NP (-LRB-:[1062..1063] -LRB-) (NN:[1063..1066] BNF) (-RRB-:[1066..1067] -RRB-))) (,:[1067..1068] ,) (NP (NP (NN:[1069..1082] dexamethasone)) (NP (-LRB-:[1083..1084] -LRB-) (NN:[1084..1087] DEX) (-RRB-:[1087..1088] -RRB-))) (,:[1088..1089] ,) (NP (NN:[1090..1097] acetone)) (,:[1097..1098] ,) (NP (NN:[1100..1107] ethanol)) (,:[1107..1108] ,) (NP (NP (NN:[1109..1118] isoniazid)) (NP (-LRB-:[1119..1120] -LRB-) (NN:[1120..1123] INH) (-RRB-:[1123..1124] -RRB-))) (,:[1124..1125] ,) (NP (NN:[1126..1143] diphenylhydantoin)) (CC:[1144..1147] and) (NP (JJ:[1148..1156] valproic) (NN:[1157..1161] acid)))))))))) (,:[1161..1162] ,) (CC:[1163..1166] and) (VP (MD:[1167..1170] can) (VP (VB:[1171..1173] be) (VP (VBN:[1175..1184] inhibited) (NP-1 (-NONE-:[1184..1184] *)) (ADVP (RB:[1185..1197] considerably)) (PP (IN:[1198..1200] by) (NP-LGS (NN:[1201..1209] SKF-525A) (CC:[1210..1213] and) (NN:[1214..1224] metyrapone))))))) (.:[1224..1225] .))) ;sentence 8 Span:1226..1383 ;alpha-Naphthoflavone (ANF) is also an inhibitor for the reaction catalyzed ;in BNF-treated rats, but stimulated the microsomal activity in DEX-treated ;rats. ;[1226..1246]:substance:"alpha-Naphthoflavone" ;[1248..1251]:substance:"ANF" ;[1265..1274]:substance:"inhibitor" ;[1305..1308]:substance:"BNF" ;[1366..1369]:substance:"DEX" (SENT (S (NP-SBJ (NP (NN:[1226..1246] alpha-Naphthoflavone)) (NP (-LRB-:[1247..1248] -LRB-) (NN:[1248..1251] ANF) (-RRB-:[1251..1252] -RRB-))) (VP (VP (VBZ:[1253..1255] is) (ADVP (RB:[1257..1261] also)) (NP-PRD (NP (DT:[1262..1264] an) (NN:[1265..1274] inhibitor)) (PP (IN:[1275..1278] for) (NP (NP (DT:[1279..1282] the) (NN:[1283..1291] reaction)) (VP (VBN:[1292..1301] catalyzed) (NP (-NONE-:[1301..1301] *)) (PP-LOC (IN:[1302..1304] in) (NP (ADJP (NN:[1305..1308] BNF) (HYPH:[1308..1309] -) (VBN:[1309..1316] treated)) (NNS:[1317..1321] rats)))))))) (,:[1321..1322] ,) (CC:[1323..1326] but) (VP (VBD:[1327..1337] stimulated) (NP (DT:[1339..1342] the) (JJ:[1343..1353] microsomal) (NN:[1354..1362] activity)) (PP-LOC (IN:[1363..1365] in) (NP (ADJP (NN:[1366..1369] DEX) (HYPH:[1369..1370] -) (VBN:[1370..1377] treated)) (NNS:[1378..1382] rats))))) (.:[1382..1383] .))) ;sentence 9 Span:1384..1704 ;Evidence has also been obtained that specific antibodies raised against ;P450IIB1, P450IA1 or IA2, P450IIE1, and P450IIIA2 inhibited the activation ;in liver microsomes from rats pretreated with PB, BNF, INH and DEX ;respectively, suggesting the possible roles of several P450 enzymes in the ;bioactivation of 3-MeO-AAB. ;[1431..1441]:substance:"antibodies" ;[1457..1465]:cyp450:"P450IIB1" ;[1467..1474]:cyp450:"P450IA1" ;[1467..1471]...[1478..1481]:cyp450:"P450"..."IA2" ;[1483..1491]:cyp450:"P450IIE1" ;[1498..1507]:cyp450:"P450IIIA2" ;[1580..1582]:substance:"PB" ;[1584..1587]:substance:"BNF" ;[1589..1592]:substance:"INH" ;[1597..1600]:substance:"DEX" ;[1656..1669]:cyp450:"P450 enzymes" ;[1694..1703]:substance:"3-MeO-AAB" (SENT (S (NP-SBJ-2 (NP (NN:[1384..1392] Evidence)) (SBAR-3 (-NONE-:[1392..1392] *ICH*))) (VP (VBZ:[1393..1396] has) (ADVP (RB:[1397..1401] also)) (VP (VBN:[1402..1406] been) (VP (VBN:[1407..1415] obtained) (NP (-NONE-:[1415..1415] *)) (SBAR-3 (IN:[1417..1421] that) (S (NP-SBJ (NP (JJ:[1422..1430] specific) (NNS:[1431..1441] antibodies)) (VP (VBN:[1442..1448] raised) (NP (-NONE-:[1448..1448] *)) (PP (IN:[1449..1456] against) (NP (NP (NN:[1457..1465] P450IIB1)) (,:[1465..1466] ,) (NP (NP (NML-1 (NN:[1467..1471] P450)) (NN:[1471..1474] IA1)) (CC:[1475..1477] or) (NP (NML-1 (-NONE-:[1477..1477] *P*)) (NN:[1478..1481] IA2))) (,:[1481..1482] ,) (NP (NN:[1483..1491] P450IIE1)) (,:[1491..1492] ,) (CC:[1493..1496] and) (NP (NN:[1498..1507] P450IIIA2)))))) (VP (VBD:[1508..1517] inhibited) (NP (DT:[1518..1521] the) (NN:[1522..1532] activation)) (PP-LOC (IN:[1533..1535] in) (NP (NN:[1536..1541] liver) (NNS:[1542..1552] microsomes))) (PP (IN:[1553..1557] from) (NP (NP (NNS:[1558..1562] rats)) (VP (VBN:[1563..1573] pretreated) (NP (-NONE-:[1573..1573] *)) (PP (IN:[1574..1578] with) (NP (NP (NN:[1580..1582] PB) (,:[1582..1583] ,) (NN:[1584..1587] BNF) (,:[1587..1588] ,) (NN:[1589..1592] INH) (CC:[1593..1596] and) (NN:[1597..1600] DEX)) (ADVP (RB:[1601..1613] respectively))))))) (,:[1613..1614] ,) (S-ADV (NP-SBJ (-NONE-:[1614..1614] *)) (VP (VBG:[1615..1625] suggesting) (NP (NP (IN:[1626..1629] the) (JJ:[1630..1638] possible) (NNS:[1639..1644] roles)) (PP (IN:[1645..1647] of) (NP (JJ:[1648..1655] several) (NN:[1656..1660] P450) (NNS:[1662..1669] enzymes)))) (PP (IN:[1670..1672] in) (NP (NP (DT:[1673..1676] the) (NN:[1677..1690] bioactivation)) (PP (IN:[1691..1693] of) (NP (NN:[1694..1703] 3-MeO-AAB))))))))))))) (.:[1703..1704] .))) ;sentence 10 Span:1705..1846 ;The results obtained with reconstituted monooxygenase systems containing ;various rat P450 enzymes are highly supportive of this conclusion. ;[1746..1759]:substance:"monooxygenase" ;[1791..1803]:cyp450:"P450 enzymes" (SENT (S (NP-SBJ (NP (DT:[1705..1708] The) (NNS:[1709..1716] results)) (VP (VBN:[1717..1725] obtained) (NP (-NONE-:[1725..1725] *)) (PP (IN:[1726..1730] with) (NP (NP (VBN:[1732..1745] reconstituted) (NN:[1746..1759] monooxygenase) (NNS:[1760..1767] systems)) (VP (VBG:[1768..1778] containing) (NP (JJ:[1779..1786] various) (NN:[1787..1790] rat) (NN:[1791..1795] P450) (NNS:[1796..1803] enzymes))))))) (VP (VBP:[1804..1807] are) (ADJP-PRD (RB:[1809..1815] highly) (JJ:[1816..1826] supportive) (PP (IN:[1827..1829] of) (NP (DT:[1830..1834] this) (NN:[1835..1845] conclusion))))) (.:[1845..1846] .))) ;sentence 11 Span:1847..2003 ;Human liver microsomal activation of 3-MeO-AAB was also inhibited to various ;extents by antibodies raised against P450IA2, P450MP, P450IIE1 and ;P450IIIA4. ;[1885..1894]:substance:"3-MeO-AAB" ;[1936..1946]:substance:"antibodies" ;[1963..1970]:cyp450:"P450IA2" ;[1972..1978]:cyp450:"P450MP" ;[1980..1988]:cyp450:"P450IIE1" ;[1993..2002]:cyp450:"P450IIIA4" (SENT (S (NP-SBJ-1 (NP (JJ:[1847..1852] Human) (NN:[1853..1858] liver) (JJ:[1859..1869] microsomal) (NN:[1870..1880] activation)) (PP (IN:[1881..1883] of) (NP (NN:[1885..1894] 3-MeO-AAB)))) (VP (VBD:[1895..1898] was) (ADVP (RB:[1899..1903] also)) (VP (VBN:[1904..1913] inhibited) (NP-1 (-NONE-:[1913..1913] *)) (PP (TO:[1914..1916] to) (NP (JJ:[1917..1924] various) (NNS:[1925..1932] extents))) (PP (IN:[1933..1935] by) (NP-LGS (NP (NNS:[1936..1946] antibodies)) (VP (VBN:[1947..1953] raised) (NP (-NONE-:[1953..1953] *)) (PP (IN:[1954..1961] against) (NP (NN:[1963..1970] P450IA2) (,:[1970..1971] ,) (NN:[1972..1978] P450MP) (,:[1978..1979] ,) (NN:[1980..1988] P450IIE1) (CC:[1989..1992] and) (NN:[1993..2002] P450IIIA4)))))))) (.:[2002..2003] .))) ;sentence 12 Span:2004..2159 ;In a reconstituted system containing purified forms of human P450, P450IA2 ;was the most active in catalyzing 3-MeO-AAB, followed by P450IIIA4 and ;P450MP. ;[2066..2070]:cyp450:"P450" ;[2072..2079]:cyp450:"P450IA2" ;[2115..2124]:substance:"3-MeO-AAB" ;[2138..2147]:cyp450:"P450IIIA4" ;[2152..2158]:cyp450:"P450MP" (SENT (S (PP (IN:[2004..2006] In) (NP (NP (DT:[2007..2008] a) (VBN:[2009..2022] reconstituted) (NN:[2023..2029] system)) (VP (VBG:[2030..2040] containing) (NP (NP (VBN:[2042..2050] purified) (NNS:[2051..2056] forms)) (PP (IN:[2057..2059] of) (NP (JJ:[2060..2065] human) (NN:[2066..2070] P450))))))) (,:[2070..2071] ,) (NP-SBJ (NN:[2072..2079] P450IA2)) (VP (VBD:[2080..2083] was) (NP-PRD (NP (DT:[2084..2087] the) (RBS:[2088..2092] most) (JJ:[2093..2099] active)) (PP (IN:[2100..2102] in) (S-NOM (NP-SBJ (-NONE-:[2102..2102] *)) (VP (VBG:[2103..2113] catalyzing) (NP (NN:[2115..2124] 3-MeO-AAB)))))) (,:[2124..2125] ,) (S-ADV (NP-SBJ (-NONE-:[2125..2125] *)) (VP (VBN:[2126..2134] followed) (NP (-NONE-:[2134..2134] *)) (PP (IN:[2135..2137] by) (NP-LGS (NN:[2138..2147] P450IIIA4) (CC:[2148..2151] and) (NN:[2152..2158] P450MP)))))) (.:[2158..2159] .))) ;sentence 13 Span:2160..2350 ;ANF, a known activator of P450IIIA-catalyzed reactions, caused an increase ;in activation of 3-MeO-AAB in human liver microsomal and P450IIIA4- and ;P450MP-containing reconstituted systems. ;[2160..2163]:substance:"ANF" ;[2173..2182]:substance:"activator" ;[2187..2195]:cyp450:"P450IIIA" ;[2253..2262]:substance:"3-MeO-AAB" ;[2294..2303]:cyp450:"P450IIIA4" ;[2309..2315]:cyp450:"P450MP" (SENT (S (NP-SBJ (NP (NN:[2160..2163] ANF)) (,:[2163..2164] ,) (NP (NP (DT:[2165..2166] a) (VBN:[2167..2172] known) (NN:[2173..2182] activator)) (PP (IN:[2183..2185] of) (NP (NML (NN:[2187..2195] P450IIIA) (HYPH:[2195..2196] -) (VBN:[2196..2205] catalyzed)) (NNS:[2206..2215] reactions))))) (,:[2215..2216] ,) (VP (VBD:[2217..2223] caused) (NP (NP (DT:[2224..2226] an) (NN:[2227..2235] increase)) (PP (IN:[2236..2238] in) (NP (NP (NN:[2239..2249] activation)) (PP (IN:[2250..2252] of) (NP (NN:[2253..2262] 3-MeO-AAB))))) (PP (IN:[2263..2265] in) (NP (NP (JJ:[2267..2272] human) (NN:[2273..2278] liver) (JJ:[2279..2289] microsomal) (NML-1 (-NONE-:[2289..2289] *P*))) (CC:[2290..2293] and) (NP (NML (NN:[2294..2303] P450IIIA4) (HYPH:[2303..2304] -) (NML-2 (-NONE-:[2304..2304] *P*))) (NML-3 (-NONE-:[2304..2304] *P*)) (NML-1 (-NONE-:[2304..2304] *P*))) (CC:[2305..2308] and) (NP (NML (NN:[2309..2315] P450MP) (HYPH:[2315..2316] -) (NML-2 (VBG:[2316..2326] containing))) (NML-3 (VBN:[2327..2340] reconstituted)) (NML-1 (NNS:[2342..2349] systems))))))) (.:[2349..2350] .))) ;sentence 14 Span:2351..2559 ;From these results it is concluded that multiple P450 enzymes in rat and ;human liver microsomes are involved in the bioactivation of 3-MeO-AAB, ;regardless of its selective induction of the rat P450IA2 gene. ;[2400..2412]:cyp450:"P450 enzymes" ;[2485..2494]:substance:"3-MeO-AAB" (SENT (S (PP (IN:[2351..2355] From) (NP (DT:[2356..2361] these) (NNS:[2362..2369] results))) (NP-SBJ-4 (NP (PRP:[2370..2372] it)) (SBAR-3 (-NONE-:[2372..2372] *EXP*))) (VP (VBZ:[2373..2375] is) (VP (VBN:[2376..2385] concluded) (NP-4 (-NONE-:[2385..2385] *)) (SBAR-3 (IN:[2386..2390] that) (S (NP-SBJ-2 (NP (JJ:[2391..2399] multiple) (NN:[2400..2404] P450) (NNS:[2405..2412] enzymes)) (PP-LOC (IN:[2413..2415] in) (NP (NP (NN:[2416..2419] rat) (NML-1 (-NONE-:[2419..2419] *P*))) (CC:[2421..2424] and) (NP (JJ:[2425..2430] human) (NML-1 (NN:[2431..2436] liver) (NNS:[2437..2447] microsomes)))))) (VP (VBP:[2448..2451] are) (VP (VBN:[2452..2460] involved) (NP-2 (-NONE-:[2460..2460] *)) (PP-CLR (IN:[2461..2463] in) (NP (NP (DT:[2464..2467] the) (NN:[2468..2481] bioactivation)) (PP (IN:[2482..2484] of) (NP (NN:[2485..2494] 3-MeO-AAB)))))) (,:[2494..2495] ,) (ADVP (RB:[2497..2507] regardless) (PP (IN:[2508..2510] of) (NP (NP (PRP$:[2511..2514] its) (JJ:[2515..2524] selective) (NN:[2525..2534] induction)) (PP (IN:[2535..2537] of) (NP (DT:[2538..2541] the) (NN:[2542..2545] rat) (NN:[2546..2553] P450IA2) (NN:[2554..2558] gene))))))))))) (.:[2558..2559] .))) ;section 15 Span:2563..2607 ;PMID: 1988174 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[2563..2567] PMID) (::[2567..2568] :) (CD:[2569..2576] 1988174) (NN:[2577..2578] -LSB-) (NNP:[2578..2584] PubMed) (::[2585..2586] -) (NN:[2587..2594] indexed) (IN:[2595..2598] for) (NNP:[2599..2607] MEDLINE-RSB-)))